-
公开(公告)号：IL319471A
公开(公告)日：2025-05-01
申请号：IL31947125
申请日：2025-03-09
Applicant: NUVIG THERAPEUTICS INC , CONLEY PAMELA B , COFFEY GREG P , KARBARZ MARK J
Inventor： CONLEY PAMELA B , COFFEY GREG P , KARBARZ MARK J
IPC: A61K39/00 , A61K39/395 , A61P29/00 , A61P37/06 , C07K16/00
Abstract: The present disclosure relates to compositions containing highly sialylated immunoglobulin Fc polypeptides having an amino acid substitution from phenylalanine to an aliphatic amino acid residue, such as alanine, at amino acid residue 241 of the Fc heavy chain. Further disclosed are methods of manufacturing the highly sialylated Fc polypeptides in a recombinant expression system. Also disclosed are methods of using the disclosed compositions for the treatment of an inflammatory disease or disorder.
-
2.发明申请COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR 审中-公开作为平板ADP受体抑制剂的化合物治疗的组合治疗
公开(公告)号：WO2008137787A3
公开(公告)日：2009-02-05
申请号：PCT/US2008062561
申请日：2008-05-02
Applicant: PORTOLA PHARM INC , CONLEY PAMELA B , ANDRE PATRICK , SINHA UMA
Inventor： CONLEY PAMELA B , ANDRE PATRICK , SINHA UMA
IPC: A61K31/235 , A61K31/422 , A61K31/435 , A61K31/517 , A61K45/06 , A61P7/00 , A61P7/02 , A61P9/00
CPC classification number: A61K31/422 , A61K31/235 , A61K31/435 , A61K31/4545 , A61K31/517 , A61K38/4846 , A61K45/06 , A61K2300/00
Abstract: The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing [4 (6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, for the treatment of thrombosis diseases.
Abstract translation: 本发明涉及药物组合物和使用含有[4（6-氟-7-甲基氨基-2,4-二氧代-1,4-二氢-2H-喹唑啉-3-基） - 苯基] - 5-氯 - 噻吩-2-基 - 磺酰脲或其药学上可接受的盐，用于治疗血栓形成疾病。
-
公开(公告)号：WO2008121721A3
公开(公告)日：2009-01-08
申请号：PCT/US2008058469
申请日：2008-03-27
Applicant: PORTOLA PHARM INC , SIMS PETER J , CONLEY PAMELA B , LUAN PENG , PHILLIPS DAVID R
Inventor： SIMS PETER J , CONLEY PAMELA B , LUAN PENG , PHILLIPS DAVID R
IPC: A61K9/127
CPC classification number: A61K9/1271 , A61K9/1272 , A61K31/685 , A61K38/177 , A61K38/46 , A61K47/6843 , A61K47/6913 , A61K2300/00
Abstract: A platelet substitute consisting of large unilamellar lipid vesicles that contain phosphatidylserine or another procoagulant (clot-promoting) phospholipid, a protein that has binding affinity for collagen or other component of the vessel wall that becomes exposed upon vessel injury, and/or a phospholipid scramblase, has been developed. This platelet substitute provides a means for selectively delivering procoagulant phospholipids and/or fatty acids to the site of vessel injury through targeted adherence to collagen or other component exposed upon vessel injury. These are particularly effective due to the combination of targeting procoagulant vesicles to a site of injury, and triggered exposure of phosphatidylserine (PS) on the surface.
Abstract translation: 包含含有磷脂酰丝氨酸或另一促凝血素（促凝血素）磷脂的大单层脂质囊泡的血小板替代物，对血管损伤时暴露于血管壁的胶原蛋白或其他成分具有结合亲和力的蛋白质和/或磷脂类 ，已经开发。 该血小板替代物提供了通过靶向粘附到血管损伤时暴露于胶原或其它组分的选择性地将促凝血磷脂和/或脂肪酸输送到血管损伤部位的手段。 由于靶向促凝血小泡与损伤部位的结合，并且触发表面上的磷脂酰丝氨酸（PS）的暴露，这些是特别有效的。
-
公开(公告)号：WO02070707A2
公开(公告)日：2002-09-12
申请号：PCT/US0149168
申请日：2001-12-18
Applicant: CURAGEN CORP , COR THERAPEUTICS INC , PADIGARU MURALIDHARA , GERLACH VALERIE L , SMITHSON GLENNDA , STONE DAVID , BIN-YANG RUEY , CONLEY PAMELA , HART MATTHEW , TOMLINSON JAMES E , TOPPER JAMES N , KEKUDA RAMESH , CASMAN STACIE J , EDINGER SCHLOMIT , MACDOUGALL JOHN R
Inventor： PADIGARU MURALIDHARA , GERLACH VALERIE L , SMITHSON GLENNDA , STONE DAVID , BIN-YANG RUEY , CONLEY PAMELA , HART MATTHEW , TOMLINSON JAMES E , TOPPER JAMES N , KEKUDA RAMESH , CASMAN STACIE J , EDINGER SCHLOMIT , MACDOUGALL JOHN R
IPC: A61K38/00 , C07K14/705 , C12N15/12 , A61K31/7088 , A61K38/17 , A61K39/395 , C07K16/28 , C12N15/63 , C12Q1/68 , G01N33/50 , G01N33/53
CPC classification number: C07K14/705 , A61K38/00 , A61K2039/505
Abstract: Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
Abstract translation: 本文公开了编码G偶联蛋白 - 受体相关多肽的核酸序列。 还公开了由这些核酸序列编码的多肽，以及免疫特异性结合多肽的抗体以及上述多肽，多核苷酸或抗体的衍生物，变体，突变体或片段。 本发明还公开了用于诊断，治疗和预防与这些新型人核酸和蛋白质中的任一种相关的病症的治疗，诊断和研究方法。
-
公开(公告)号：WO2008121721A2
公开(公告)日：2008-10-09
申请号：PCT/US2008/058469
申请日：2008-03-27
Applicant: PORTOLA PHARMACEUTICALS, INC. , SIMS, Peter, J. , CONLEY, Pamela, B. , LUAN, Peng , PHILLIPS, David, R.
Inventor： SIMS, Peter, J. , CONLEY, Pamela, B. , LUAN, Peng , PHILLIPS, David, R.
IPC: C07K16/00
CPC classification number: A61K9/1271 , A61K9/1272 , A61K31/685 , A61K38/177 , A61K38/46 , A61K47/6843 , A61K47/6913 , A61K2300/00
Abstract: A platelet substitute consisting of large unilamellar lipid vesicles that contain phosphatidylserine or another procoagulant (clot-promoting) phospholipid, a protein that has binding affinity for collagen or other component of the vessel wall that becomes exposed upon vessel injury, and/or a phospholipid scramblase, has been developed. This platelet substitute provides a means for selectively delivering procoagulant phospholipids and/or fatty acids to the site of vessel injury through targeted adherence to collagen or other component exposed upon vessel injury. These are particularly effective due to the combination of targeting procoagulant vesicles to a site of injury, and triggered exposure of phosphatidylserine (PS) on the surface.
Abstract translation: 包含含有磷脂酰丝氨酸或另一促凝血素（促凝血素）磷脂的大单层脂质囊泡的血小板替代物，对血管损伤时暴露于血管壁的胶原蛋白或其他成分具有结合亲和力的蛋白质和/或磷脂类 ，已经开发。 该血小板替代物提供了通过靶向粘附到血管损伤时暴露于胶原或其它组分的选择性地将促凝血磷脂和/或脂肪酸输送到血管损伤部位的手段。 由于靶向促凝血小泡与损伤部位的结合，并且触发表面上的磷脂酰丝氨酸（PS）的暴露，这些是特别有效的。
-
Patent Agency Ranking
公开(公告)号：WO2007112367A2
公开(公告)日：2007-10-04
申请号：PCT/US2007/064956
申请日：2007-03-26
Applicant: PORTOLA PHARMACEUTICALS, INC. , ZWAAL, Robert F.A. , CONLEY, Pamela, B.
Inventor： ZWAAL, Robert F.A. , CONLEY, Pamela, B.
IPC: A61K31/4745
CPC classification number: A61K31/4745
Abstract: Methods of modulating platelet procoagulant response are taught herein. Inhibition of platelet procoagulant response with agents that inhibit the Ca 2 +-sensitive K + channels, or Gardos channels, preferably while maintaining platelet bleeding arrest function, may be used to treat a variety of disorders.
Abstract translation: 本文教导了调节血小板促凝血反应的方法。 可以使用抑制抑制Ca 2+ 2敏感性高通道或Gardos通道的药物对血小板促凝血反应的抑制，优选在维持血小板渗血阻滞功能的同时治疗 各种疾病。
-
公开(公告)号：WO0216599A2
公开(公告)日：2002-02-28
申请号：PCT/US0126510
申请日：2001-08-27
Applicant: CURAGEN CORP , COR THERAPEUTICS INC , BURGESS CATHERINE E , CONLEY PAMELA B , GROSSE WILLIAM M , HART MATTHEW , KEKUDA RAMESH , SHIMKETS RICHARD A , SPYTEK KIMBERLY A , SZEKERES EDWARD S JR , TOMLINSON JAMES E , TOPPER JAMES N , YANG RUEY BIN
Inventor： BURGESS CATHERINE E , CONLEY PAMELA B , GROSSE WILLIAM M , HART MATTHEW , KEKUDA RAMESH , SHIMKETS RICHARD A , SPYTEK KIMBERLY A , SZEKERES EDWARD S JR , TOMLINSON JAMES E , TOPPER JAMES N , YANG RUEY-BIN
Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses tehrapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
Abstract translation: 本文公开了编码新型多肽的核酸序列。 还公开了由这些核酸序列编码的多肽，以及免疫特异性结合多肽的抗体以及前述多肽，多核苷酸或抗体的衍生物，变体，突变体或片段。 本发明还公开了用于诊断，治疗和预防与这些新型人核酸和蛋白质中的任何一种相关的病症的治疗，诊断和研究方法。
-
公开(公告)号：WO2010117729A1
公开(公告)日：2010-10-14
申请号：PCT/US2010/029064
申请日：2010-03-29
Applicant: PORTOLA PHARMACEUTICALS, INC. , SINHA, Uma , LU, Genmin , CONLEY, Pamela B.
Inventor： SINHA, Uma , LU, Genmin , CONLEY, Pamela B.
CPC classification number: C12N9/6432 , A61K38/482 , A61K38/4826 , A61K38/4833 , A61K38/4846 , A61K38/4853 , A61K39/00 , A61K47/60 , C12Y304/21006
Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
Abstract translation: 本发明涉及靶向因子Xa的抗凝剂的解毒剂。 解毒剂是与因子Xa抑制剂结合的因子X和因子Xa蛋白衍生物，从而基本上中和它们，但不组装到凝血酶原酶复合物中。 本文所述的衍生物缺乏或具有降低的内在凝结剂活性。 本文公开的是使用因子Xa抑制剂正在进行抗凝治疗的患者中的抗凝，停止或预防出血的方法。
-
公开(公告)号：WO2008121721A8
公开(公告)日：2009-07-30
申请号：PCT/US2008058469
申请日：2008-03-27
Applicant: PORTOLA PHARM INC , SIMS PETER J , CONLEY PAMELA B , LUAN PENG , PHILLIPS DAVID R
Inventor： SIMS PETER J , CONLEY PAMELA B , LUAN PENG , PHILLIPS DAVID R
IPC: A61K9/127
CPC classification number: A61K9/1271 , A61K9/1272 , A61K31/685 , A61K38/177 , A61K38/46 , A61K47/6843 , A61K47/6913 , A61K2300/00
Abstract: A platelet substitute consisting of large unilamellar lipid vesicles that contain phosphatidylserine or another procoagulant (clot-promoting) phospholipid, a protein that has binding affinity for collagen or other component of the vessel wall that becomes exposed upon vessel injury, and/or a phospholipid scramblase, has been developed. This platelet substitute provides a means for selectively delivering procoagulant phospholipids and/or fatty acids to the site of vessel injury through targeted adherence to collagen or other component exposed upon vessel injury. These are particularly effective due to the combination of targeting procoagulant vesicles to a site of injury, and triggered exposure of phosphatidylserine (PS) on the surface.
Abstract translation: 由含有磷脂酰丝氨酸或另一种促凝血（促凝血）磷脂的大单层脂质囊泡组成的血小板替代物，对血管损伤时暴露的胶原或血管壁的其他成分具有结合亲和力的蛋白质和/或磷脂酶 ， 已经被开发出来。 该血小板替代物提供了通过靶向粘附胶原蛋白或血管损伤时暴露的其他成分，将促凝血磷脂和/或脂肪酸选择性递送至血管损伤部位的手段。 由于将促凝血囊泡靶向损伤部位并引发表面上的磷脂酰丝氨酸（PS）暴露，这些特别有效。
-
公开(公告)号：WO2008137753A3
公开(公告)日：2008-11-13
申请号：PCT/US2008/062518
申请日：2008-05-02
Applicant: PORTOLA PHARMACEUTICALS, INC. , SCARBOROUGH, Carroll, Anna, Crew , GRETLER, Daniel, D. , CONLEY, Pamela, B. , ANDRE, Patrick , HUTCHALEELAHA, Athiwat , PHILLIPS, David, R. , PANDEY, Anjali , WOLIN, Huang
Inventor： GRETLER, Daniel, D. , CONLEY, Pamela, B. , ANDRE, Patrick , HUTCHALEELAHA, Athiwat , PHILLIPS, David, R. , PANDEY, Anjali , WOLIN, Huang
IPC: A61K31/216 , A61K31/517 , A61P7/02
Abstract: The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: (I) alone or in combination with a second agent which can be aspirin or a thrombolytic agent.
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.023 seconds)
